Literature DB >> 25061651

[Comparison of recurrence patterns in esophageal carcinoma after surgery alone and surgery after neoadjuvant chemoradiotherapy: a secondary analysis of the CROSS study].

Matthias G Hautmann, Oliver Kölbl.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25061651     DOI： 10.1007/s00066-014-0682-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.

Authors:  S G Urba; M B Orringer; A Turrisi; M Iannettoni; A Forastiere; M Strawderman
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

Review 3.  [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy].

Authors:  F Lordick; K Ott; A Sendler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

4.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

5.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

6.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

7.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

8.  A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

Authors:  J-L Lee; S I Park; S-B Kim; H-Y Jung; G H Lee; J-H Kim; H-Y Song; K-J Cho; W-K Kim; J-S Lee; S-H Kim; Y-I Min
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

9.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.

Authors:  E Le Prise; P L Etienne; B Meunier; G Maddern; M Ben Hassel; D Gedouin; D Boutin; J P Campion; B Launois
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.